Acute decompensated heart failure. Combined systolic (congestive) and diastolic (congestive) heart failure
Conditions
Interventions
Intervention 1: Intervention group:? They will receive acetazolamide 500 mg on day zero, then 250 mg twice daily for three days.?. Intervention 2: Control group: ?They will receive placebo equivalent
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Informed consent to participate in the study Age over 18 years Diagnosis of ADHF with at least one sign of congestion (such as edema, evidence of abdominal ascites on ultrasound, evidence of pulmonary edema on chest radiography or chest ultrasound) Maintenance therapy with an oral loop diuretic, at least 20 mg furosemide or 10 mg torsemide, one month prior to hospitalization Use of SGLT2i, including dapagliflozin and empagliflozin, for at least one month prior to hospitalization NT-proBNP more than 1000 ng/mL or BNP more than 250 ng/mL
Exclusion criteria
Exclusion criteria: Hospitalized due to Acute Coronary Syndrome History of congenital heart disease that requires surgery Systolic blood pressure less than 90 mmHg or mean arterial pressure less than 65 mmHg despite vasopressor administration Estimated glomerular filtration rate less than 20 mL/min/1.73m² Use of acetazolamide during hospitalization or prior to study entry Use of diuretic medications except for mineralocorticoid antagonists such as spironolactone and eplerenone and loop diuretics such as furosemide Pregnant or breastfeeding women Hyperchloremic metabolic acidosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ?Decongestion and edema resolustion. Timepoint: Day zero at the beginning then daily for three days after randomization. Method of measurement: Clinical examination and recording congestion score. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSomaye Mohammadi
Tehran University of Medical Sciences
Outcome results
None listed